In Vitro Testing of Trichomonas vaginalis Drug Susceptibility: Evaluation of Minimal Lethal Concentrations for Metronidazole and Tinidazole That Correspond With Treatment Failure

• Authors: Peter Augostini, Centers for Disease Control and Prevention; Erin LP Bradley, Emory University; Brian H Raphael, Centers for Disease Control and Prevention; Evan W Secor, Centers for Disease Control and Prevention
• Journal Title: SEXUALLY TRANSMITTED DISEASES
• Volume: Volume 50, Number 6
• Publisher: Lippincott, Williams & Wilkins | 2023-06-01, Pages 370-373
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1097/OLQ.0000000000001788
• Subjects: Health Sciences, Public Health
• Keywords: Treatment Failure

Abstract

The only drugs approved by the US Food and Drug Administration for oral treatment of trichomoniasis belong to the 5-nitroimidazole group. Most individuals infected with Trichomonas vaginalis can be cured with a standard treatment of metronidazole or tinidazole, but it is estimated that more than 159,000 people fail treatment each year. Although a minimal lethal concentration (MLC) corresponding to treatment failure has been reported for metronidazole, the MLC for tinidazole associated with treatment failure has not been determined. We conducted a study using T. vaginalis isolates from women with reported treatment success or failure to determine these values.